{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:02:36Z","timestamp":1794808956525,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital\u2019s funds for Health Improvement and Research","award":["CFH2024-2-2175"],"award-info":[{"award-number":["CFH2024-2-2175"]}]},{"name":"Investigator-Initiated trial Program of the Internal Research Fund, Beijing Ditan Hospital, Capital Medical University","award":["DTIIT202501"],"award-info":[{"award-number":["DTIIT202501"]}]},{"name":"Collaboration, Consistency, and Innovation Program of the National Center for Infectious Diseases","award":["GCST20250101"],"award-info":[{"award-number":["GCST20250101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13035-w","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T17:05:34Z","timestamp":1773075934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of bictegravir, emtricitabine, and tenofovir alafenamide (BIC\/FTC\/TAF) versus efavirenz, lamivudine, and tenofovir disoproxil fumarate (EFV+3TC\u2009+\u2009TDF) in late-presenting people with HIV rapid initial antiretroviral therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Qinlan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"13035_CR1","unstructured":"UNAIDS, Global. AIDS Update 2024. Joint United Nations Programme on HIV\/AIDS; 2024."},{"key":"13035_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/135965350701200612","volume":"12","author":"M Battegay","year":"2007","unstructured":"Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther. 2007;12:841\u201351.","journal-title":"Antivir Ther"},{"key":"13035_CR3","doi-asserted-by":"publisher","first-page":"752782","DOI":"10.3389\/fimmu.2021.752782","volume":"12","author":"CS Wong","year":"2021","unstructured":"Wong CS, Buckner CM, Lage SL, Pei L, Assis FL, Dahlstrom EW, Anzick SL, Virtaneva K, Rupert A, Davis JL, Zhou T, Laidlaw E, Manion M, Galindo F, Anderson M, Seamon CA, Sneller MC, Lisco A, Deleage C, Pittaluga S, Moir S, Sereti I. Rapid Emergence of T Follicular Helper and Germinal Center B Cells Following Antiretroviral Therapy in Advanced HIV Disease. Front Immunol. 2021;12:752782. https:\/\/doi.org\/10.3389\/fimmu.2021.752782.","journal-title":"Front Immunol"},{"key":"13035_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/QAI.0000000000001134","volume":"74","author":"CD Pilcher","year":"2017","unstructured":"Pilcher CD, Ospina-Norvell C, Dasgupta A, Jones D, Hartogensis W, Torres S, Calderon F, Demicco E, Geng E, Gandhi M, Havlir DV, Hatano H. The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. J Acquir Immune Defic Syndr. 2017;74:44\u201351. https:\/\/doi.org\/10.1097\/QAI.0000000000001134.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"13035_CR5","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1097\/QAD.0000000000002937","volume":"35","author":"P Pathela","year":"2021","unstructured":"Pathela P, Jamison K, Braunstein SL, Borges CM, Lazar R, Mikati T, Daskalakis D, Blank S. Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression. AIDS. 2021;35:1805\u201312. https:\/\/doi.org\/10.1097\/QAD.0000000000002937.","journal-title":"AIDS"},{"key":"13035_CR6","unstructured":"in Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy WHO Guidelines Approved by the Guidelines Review Committee (2017)."},{"key":"13035_CR7","unstructured":"in Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach WHO Guidelines Approved by the Guidelines Review Committee (2021)."},{"key":"13035_CR8","unstructured":"Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021."},{"key":"13035_CR9","unstructured":"Adolescents P. o. A. G. f. A. a. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv."},{"key":"13035_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40265-019-01101-4","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Correction to: Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs. 2019;79:687. https:\/\/doi.org\/10.1007\/s40265-019-01101-4.","journal-title":"Drugs"},{"key":"13035_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M14-1084","volume":"161","author":"JL Lennox","year":"2014","unstructured":"Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, Team AA. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461\u201371. https:\/\/doi.org\/10.7326\/M14-1084.","journal-title":"Ann Intern Med"},{"key":"13035_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/QAI.0000000000003273","volume":"94","author":"MA Bousmah","year":"2023","unstructured":"Bousmah MA, Protopopescu C, Mpoudi-Etame M, Bassega O, Maradan P, Olinga G, Varloteaux J, Tovar-Sanchez M, Delaporte T, Kouanfack E, Boyer C, S., Group NAS. Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial). J Acquir Immune Defic Syndr. 2023;94:262\u201372. https:\/\/doi.org\/10.1097\/QAI.0000000000003273.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"13035_CR13","unstructured":"Sciences G. Switching TDF\/\u200bFTC\/\u200bEFV to TDF\/\u200bFTC\/\u200bRPV VS Continuing TDF\/\u200bFTC\/\u200bEFV in HIV patients with complete virological suppression (STEREOS). 2017. https:\/\/clinicaltrials.gov\/study\/NCT03251690."},{"key":"13035_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/ciae012","volume":"79","author":"R Wang","year":"2024","unstructured":"Wang R, Sun L, Wang X, Zhai Y, Wang L, Ma P, Wu C, Zhou Y, Chen R, Wang R, Zhang F, Hua W, Li A, Xia W, Gao Y, Li R, Lv S, Shao Y, Cao Y, Zhang T, Wu H, Cai C, Dai L. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial. Clin Infect Dis. 2024;79:169\u201376. https:\/\/doi.org\/10.1093\/cid\/ciae012.","journal-title":"Clin Infect Dis"},{"key":"13035_CR15","unstructured":"Adolescents P. o. A. G. f. A. a. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2025."},{"key":"13035_CR16","unstructured":"Organization WH. WHO guidelines for the prevention and treatment of HIV. World Health Organization; 2023."},{"key":"13035_CR17","first-page":"1","volume":"58","author":"JE Kaplan","year":"2009","unstructured":"Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, Centers for Disease C, Prevention N, Institutes of H, America H. I. V. M. A. o. t. I. D. S. o. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1\u2013207. quiz CE201-204.","journal-title":"MMWR Recomm Rep"},{"key":"13035_CR18","doi-asserted-by":"publisher","first-page":"32947","DOI":"10.1038\/srep32947","volume":"6","author":"M Hoenigl","year":"2016","unstructured":"Hoenigl M, Chaillon A, Moore DJ, Morris SR, Mehta SR, Gianella S, Amico KR, Little SJ. Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis. Sci Rep. 2016;6:32947. https:\/\/doi.org\/10.1038\/srep32947.","journal-title":"Sci Rep"},{"key":"13035_CR19","doi-asserted-by":"publisher","unstructured":"Fokam J, Chenwi CA, Tala V, Takou D, Santoro MM, Teto G, Dambaya B, Anubodem F, Semengue ENJ, Beloumou G, Djupsa S, Assomo E, Fokunang C, Alteri C, Billong S, Bouba NP, Ajeh R, Colizzi V, Mbanya D, Ceccherini-Silberstein F, Perno CF, Ndjolo A. Pre-Treatment HIV Drug Resistance and Genetic Diversity in Cameroon: Implications for First-Line Regimens. Viruses. 2023;15. https:\/\/doi.org\/10.3390\/v15071458.","DOI":"10.3390\/v15071458"},{"key":"13035_CR20","doi-asserted-by":"publisher","first-page":"2373105","DOI":"10.1080\/21505594.2024.2373105","volume":"15","author":"M Zhang","year":"2024","unstructured":"Zhang M, Ma Y, Wang Z, Wang G, Wang Q, Li X, Lin F, Zhang C. Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017\u20132021. Virulence. 2024;15:2373105. https:\/\/doi.org\/10.1080\/21505594.2024.2373105.","journal-title":"Virulence"},{"key":"13035_CR21","doi-asserted-by":"publisher","first-page":"1510916","DOI":"10.3389\/fcimb.2025.1510916","volume":"15","author":"X Lu","year":"2025","unstructured":"Lu X, Li Y, Liu M, Wang Y, An N, Sun D, Li Q. Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018\u20132022. Front Cell Infect Microbiol. 2025;15:1510916. https:\/\/doi.org\/10.3389\/fcimb.2025.1510916.","journal-title":"Front Cell Infect Microbiol"},{"key":"13035_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","volume":"18","author":"RK Gupta","year":"2018","unstructured":"Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, Kaleebu P, Watera C, Aghokeng A, Mutenda N, Dzangare J, Hone S, Hang ZZ, Garcia J, Garcia Z, Marchorro P, Beteta E, Giron A, Hamers R, Inzaule S, Frenkel LM, Chung MH, de Oliveira T, Pillay D, Naidoo K, Kharsany A, Kugathasan R, Cutino T, Hunt G, Avila Rios S, Doherty M, Jordan MR, Bertagnolio S. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18:346\u201355. https:\/\/doi.org\/10.1016\/S1473-3099(17)30702-8.","journal-title":"Lancet Infect Dis"},{"key":"13035_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/QAD.0000000000003182","volume":"36","author":"LE Hermans","year":"2022","unstructured":"Hermans LE, Hofstra LM, Schuurman R, Ter Heine R, Burger DM, Talboom SAJ, De Jong D, Tempelman HA, Venter WDF, Nijhuis M, Wensing AM. J. HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment. AIDS. 2022;36:923\u201331. https:\/\/doi.org\/10.1097\/QAD.0000000000003182.","journal-title":"AIDS"},{"key":"13035_CR24","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(17)32299-7.","journal-title":"Lancet"},{"key":"13035_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","volume":"15","author":"M Oliveira","year":"2018","unstructured":"Oliveira M, Ibanescu RI, Anstett K, Mesplede T, Routy JP, Robbins MA, Brenner BG, Montreal Primary H. I. V. C. S. G. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15:56. https:\/\/doi.org\/10.1186\/s12977-018-0440-3.","journal-title":"Retrovirology"},{"key":"13035_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1681\/ASN.V191061","volume":"1","author":"JS Berns","year":"1991","unstructured":"Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol. 1991;1:1061\u201380. https:\/\/doi.org\/10.1681\/ASN.V191061.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13035-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13035-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:39:45Z","timestamp":1776328785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13035-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13035"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13035-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involving human participants was reviewed and approved by Human Science Ethical Committee of Beijing Ditan Hospital, Capital Medical University. Written informed consent for participation was not required for this study in accordance with the institutional requirements due to a retrospective study. All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"773"}}